Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
- Price Settlement Rate Down to Levels before Emergency Call
February 21, 2011
- Takeda Begins PIII Trial of Alogliptin in China
February 21, 2011
- New Drugs Improve Range of Options for Osteoporosis: 1
February 21, 2011
- Korosho to Carry Out Case Studies to Promote Use of Generics
February 21, 2011
- Janssen Launches Once-Daily Fentanyl Patch
February 21, 2011
- No Differences in Impurity Contents in 6 Cisplatin Products: NIHS Study Group
February 21, 2011
- Astellas Licenses Fidaxomicin from Optimer
February 21, 2011
- Sawai: First 3-Qtr Sales, Profits Show Double-Digit Growth
February 21, 2011
- Astellas Creates Sales Subsidiary in Australia
February 21, 2011
- PHARMA JAPAN Lexicon: 47
February 21, 2011
- Santen Allies with DBJ
February 21, 2011
- Korosho to Review Current Risk Classification of OTC Drugs
February 21, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…